TheraBionic P1 therapy is a new FDA-approved treatment when other cancer therapies have failed.
Often patients with advanced HCC* for whom other cancer therapies have failed have no alternative beyond hospice care. After more than two decades of studies of patients with advanced liver cancer for whom other cancer therapies have failed, the TheraBionic P1 device has been found to extend survival without adverse events.
* The TheraBionic P1 device is FDA approved for treatment in patients 18 and older with hepatocellular carcinoma (HCC), the most common form of liver cancer, who have failed first and second line therapies.
Dr. Boris Pasche explains more:
Patient FAQ
How can I obtain the TheraBionic P1 treatment?
Speak with your physician. The device is available for patients who have received a prescription from their physician. Currently, the TheraBionic P1 device is FDA approved for patients 18 years and older with advanced hepatocellular carcinoma (HCC), for whom first and second line therapies have failed or who do not tolerate these therapies.
How does the TheraBionic P1 device work?
The TheraBionic P1 device is a small, portable device that delivers tumor-specific radio frequency electromagnetic fields throughout the body via a spoon-shaped antenna, which is placed on the patient’s tongue during treatment. The radio frequency electromagnetic fields are tumor-specific and block the growth of tumor cells without affecting normal cells. Treatment is administered for one hour, three times daily.
Will I have to go to my doctor’s office or the hospital?
Treatment with the TheraBionic P1 device is administered at home.The device comes with a carrying case, wireless charging docking station, a patient spoon with connecting cable to the TheraBionic P1 device, power supply to power the docking station, and single use activation cards to upload activation time into the therapeutic device.
Where should the TheraBionic P1 device be placed during treatment?
The TheraBionic P1 device should be preferably placed on the thigh or the abdomen of the patient during treatment.
Does the use of the TheraBionic P1 device require specialized training?
Use of the TheraBionic P1 device does not require specialized training.
Will I feel anything when receiving treatment with the TheraBionic P1 device?
Patients receiving treatment with the TheraBionic P1 device usually do not feel anything while receiving treatment. The levels of radio frequency electromagnetic fields delivered to patients during treatment is at least 100 times lower than the levels of electromagnetic fields delivered by cellphones kept close to the body.
Why not place the spoon-shaped antenna directly over the liver during treatment?
The electrical resistance of the human skin varies from individual to individual and the spoon-shaped antenna applied to the skin will not reliably deliver therapeutic levels of radio frequency electromagnetic fields throughout the body. When the spoon-shaped antenna is placed on the patient’s tongue, the radio frequency electromagnetic fields are delivered throughout the body.
Is it safe for other individuals to be close to me while I received treatment with the TheraBionic P1 device?
There is no risk to you or anyone near you, as the emitting power of the TheraBionic P1 is very low. It is recommended not to have any physical contact with other persons during treatment as this may alter the absorption of electromagnetic fields in the patient’s body.
R. Perrier, diagnosed with HCC in 2011, pictured with his wife E. Perrier. The TheraBionic P1 device was the sole treatment administered between 2013 and 2017 following intolerable side effects from previous therapies.
“The TheraBionic device provided my husband several additional years of life. I hope that other patients will be able to benefit from the device in the future.”
– E. Perrier, wife of former TheraBionic P1 device user
-
My name is Edeline Perrier and I live in Lyon, France. I am the wife of Robert Perrier, who passed away in October 2017 at the age of 85. I have asked my family friend to speak on my behalf as my English is limited.
In January 2011, my husband was diagnosed with hepatocellular carcinoma. He underwent resection of his tumor shortly after. In May 2011, we learned that his disease has recurred with several new legions. He received additional treatments in the form of chemoembolization in June. In July, the disease came back, and he began treatment with Sorafenib in August 2011. As I had heard about the TheraBionic device for the treatment of hepatocellular carcinoma, I approached Professor Pasche to request compassionate use of the device. My husband began receiving treatment with the device in September 2011. With these combined treatments, my husband’s disease shrank dramatically, but he was forced to stop Sorafenib as of February 2013 because of his intolerable hand and foot pain despite several dose reductions. However, he continued receiving treatment with the TheraBionic device at home for several years, enjoying an excellent quality of life, able to travel with me, and walk his dog on a daily basis.
In April 2017, he broke his hip. After this fall, he never fully recovered his prior level of energy and died of kidney failure in October 2017 having decided that he did not want dialysis.
I am extremely thankful to Professor Pasche to have been able to use the TheraBionic device which kept my husband alive without any side effects for several years. It is my personal opinion that the TheraBionic device has provided my husband several additional years of life. I hope that other patients will be able to benefit from the device in the future.
The future of cancer treatment
The TheraBionic P1 device is currently being studied as first and second line treatment of HCC, meaning the TheraBionic P1 device is used with another treatment agent. The device is also being studied as a first line or initial treatment for stage 4 pancreatic cancer.
Pending the findings of these studies, TheraBionic Inc. will pursue additional approval as first and second line therapy for the treatment of liver and other forms of cancer including breast, prostate, ovarian, cholangiocarcinoma, and brain tumors.
We are also investigating the effectiveness of tumor-specific modulation frequencies for early diagnosis of cancer.
*The TheraBionic P1 device is FDA-approved for treatment of hepatocellular carcinoma, the most common form of liver cancer. Patients 18 and older with advanced HCC who have failed first and second line therapies are eligible for treatment with the TheraBionic P1 device.
Patient Contact Form
Want to know more about TheraBionic P1 therapy?